458 related articles for article (PubMed ID: 27512838)
1. Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy.
Cao L; Cai G; Xu F; Yang ZZ; Yu XL; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
Medicine (Baltimore); 2016 Aug; 95(32):e4230. PubMed ID: 27512838
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
[TBL] [Abstract][Full Text] [Related]
3. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy.
Lanning RM; Morrow M; Riaz N; McArthur HL; Dang C; Moo TA; El-Tamer M; Krause K; Siu C; Hsu M; Zhang Z; Pei X; McCormick B; Powell SN; Ho A
Ann Surg Oncol; 2015 Aug; 22(8):2517-25. PubMed ID: 25564167
[TBL] [Abstract][Full Text] [Related]
5. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
6. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
[TBL] [Abstract][Full Text] [Related]
7. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
9. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
Rier HN; Levin MD; van Rosmalen J; Bos MMEM; Drooger JC; de Jong P; Portielje JEA; Elsten EMP; Ten Tije AJ; Sleijfer S; Jager A
Oncologist; 2017 Aug; 22(8):901-909. PubMed ID: 28533475
[TBL] [Abstract][Full Text] [Related]
10. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.
Abdulkarim BS; Cuartero J; Hanson J; Deschênes J; Lesniak D; Sabri S
J Clin Oncol; 2011 Jul; 29(21):2852-8. PubMed ID: 21670451
[TBL] [Abstract][Full Text] [Related]
12. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
[TBL] [Abstract][Full Text] [Related]
13. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer.
Kim MM; Dawood S; Allen P; Sahin AA; Woodward WA; Smith BD; Strom EA; Hunt KK; Meric-Bernstam F; Gonzalez-Angulo AM; Buchholz TA
Cancer; 2012 Oct; 118(20):4936-43. PubMed ID: 22511276
[TBL] [Abstract][Full Text] [Related]
14. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
15. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
[TBL] [Abstract][Full Text] [Related]
16. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
17. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of apex axillary invasion for locoregional recurrence and effect of postmastectomy radiotherapy on overall survival in node-positive breast cancer patients.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Alagol H
World J Surg; 2004 Mar; 28(3):236-41. PubMed ID: 14961194
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
20. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Bellon JR; Guo H; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Hudis CA; Krop I; Burstein HJ; Winer EP; Tolaney SM
Breast Cancer Res Treat; 2019 Jul; 176(2):303-310. PubMed ID: 31004299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]